{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:20Z","timestamp":1791874700191,"version":"4.3.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T00:00:00Z","timestamp":1504569600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s00198-017-4215-9","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T17:06:55Z","timestamp":1504631215000},"page":"3431-3438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk"],"prefix":"10.1007","volume":"28","author":[{"given":"M. A.","family":"Mignot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Taisne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Legroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cortet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Paccou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,5]]},"reference":[{"key":"4215_CR1","first-page":"1535","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348:1535\u20131541","journal-title":"Fracture Intervention Trial Research Group Lancet"},{"key":"4215_CR2","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"4215_CR3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) HORIZON Pivotal Fracture Trial. Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"4215_CR4","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS et al (2007) HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809","journal-title":"N Engl J Med"},{"key":"4215_CR5","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.1893","volume":"28","author":"L Gedmintas","year":"2013","unstructured":"Gedmintas L, Solomon DH, Kim SC (2013) Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 28:1729\u20131737","journal-title":"J Bone Miner Res"},{"key":"4215_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323","journal-title":"J Bone Miner Res"},{"key":"4215_CR7","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"24","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 24:2927\u20132938","journal-title":"JAMA"},{"key":"4215_CR8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243\u2013254","journal-title":"J Bone Miner Res"},{"key":"4215_CR9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jbspin.2016.02.004","volume":"83","author":"J Paccou","year":"2016","unstructured":"Paccou J (2016) Management after first-line antiresorptive treatment for postmenopausal osteoporosis. Joint Bone Spine 83:373\u2013375","journal-title":"Joint Bone Spine"},{"key":"4215_CR10","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00198-008-0604-4","volume":"19","author":"JR Curtis","year":"2008","unstructured":"Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int 19:1613\u20131620","journal-title":"Osteoporos Int"},{"key":"4215_CR11","unstructured":"Adams AL, Adams JL, Raebel MA, et al. Bisphosphonate drug holiday and fracture risk. Abstract 1045. Presented at: American Society for Bone and Mineral Research 2014 Sept 12\u201315, 2014; Houston, Texas"},{"key":"4215_CR12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jbspin.2012.02.014","volume":"79","author":"K Briot","year":"2012","unstructured":"Briot K, Cortet B, Thomas T et al (2012) 2012 Update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 79:304\u2013313","journal-title":"Joint Bone Spine"},{"key":"4215_CR13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16\u201335","journal-title":"J Bone Miner Res"},{"key":"4215_CR14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00198-015-3453-y","volume":"27","author":"SL Silverman","year":"2016","unstructured":"Silverman SL, Adachi JD, Dennison E, International Osteoporosis Foundation Epidemiology\/Quality of Life Working Group (2016) Bisphosphonate drug holidays: we reap what we sow. Osteoporos Int 27:849\u2013852","journal-title":"Osteoporos Int"},{"key":"4215_CR15","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","volume":"99","author":"F Cosman","year":"2014","unstructured":"Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, Cummings SR, Black DM (2014) Reassessment of fracture risk in women after 3 years of treatment with xoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab 99:4546\u20134554","journal-title":"J Clin Endocrinol Metab"},{"key":"4215_CR16","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","volume":"174","author":"DC Bauer","year":"2014","unstructured":"Bauer DC, Schwartz A, Palermo L et al (2014) Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy. JAMA Intern Med 174:1126\u20131134","journal-title":"JAMA Intern Med"},{"key":"4215_CR17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4158\/EP12425.OR","volume":"19","author":"M Chiha","year":"2013","unstructured":"Chiha M, Myers LE, Ball CA, Sinacore JM, Camacho PM (2013) Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting. Endocr Pract 19:989\u2013994","journal-title":"Endocr Pract"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-017-4215-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4215-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-017-4215-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T09:33:24Z","timestamp":1510565604000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-017-4215-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,5]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["4215"],"URL":"https:\/\/doi.org\/10.1007\/s00198-017-4215-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,5]]}}}